India, June 5 -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark's Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat'2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254].According to IQVIA' sales data for the 12-month period ending April 2026, the Vimpat' Injection market3 achieved annual sales of approximately $15.2 million.
Published by HT Digital Content Services with permission from Pivotal Sources....